Endpoints News 2026年6月7日 #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
FierceBiotech 2026年6月7日 ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
FierceBiotech 2026年6月6日 ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Cell 2026年6月6日 Deep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation
FierceBiotech 2026年6月6日 ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
Endpoints News 2026年6月6日 #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
FierceBiotech 2026年6月6日 ‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
Brady Corporation 2026年6月6日 Label Maker Market Forecast Points Higher Toward 2035, Driven by Commercial Micro-Enterprise Demand - IndexBox
Novo Nordisk 2026年6月5日 Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire